Effect of Diet and Exercise Program for Chronic Hepatitis C with Insulin Resistance - Impact on liver function and virological response to Pegylated Interferon alpha-2b/Ribavirin-

Effect of Diet and Exercise Program for Chronic Hepatitis C with Insulin Resistance - Impact on liver function and virological response to Pegylated Interferon alpha-2b/Ribavirin- - Effect of Diet and Exercise Program for Chronic Hepatitis C with Insulin Resistance (EPOCH)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003044

Enrollment

Registered

2010-01-15

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Patients undergo the following dietary and exercise intervention for more than 3 months. Diet therapy: Nutritional education by dietitian. Record of diet diary. Exercise therapy: Instruction based o

exercise guide 2006&quot

publishing by Ministry of Health, Labour and Welfare in Japan. Record of exercise diary.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients satisfying all the below are eligible. (1)Chronic hepatitis C (2)HCV genotype 1b or 2 with high viral load (5.0 or >5.0 logIU/mL) (3)Insulin resistance (HOMA-IR 2 or >2)

Exclusion criteria

Exclusion criteria: (1)pregnancy, its possibility or lactation (2)hypersensitivity to IFN, pegylated IFN or ribavirin (3)uncontrollable cardiac disease (4)hemoglobinopathy (5)creatinine clearance less than 50 mL/min (6)severe mental illnesses such as depression or past history (7)decompensated liver disease (8)autoimmune hepatitis (9)taking medication for DM or poor control of blood glucose levels

Design outcomes

Primary

Measure	Time frame
(1) the degree of improvement in liver function (2) the virological responce rate	—

Secondary

Measure	Time frame
(1) the degree of improvement in HOMA-IR (2) the change of body weight and waist circumference	—

Countries

Japan

Contacts

Public ContactYukie Watanabe

Saga Medical School Division of Hepatology, Diabetology & Endocrinology

watanab2@cc.saga-u.ac.jp0952-34-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026